手机验证
LRRK2 Antibody
synthetic peptide surrounding Gly2090 of human LRRK2
W
Rabbit
大量
详见MSDS文件
CST
详见说明书
H
2
-20°c
100 ul (10 western blots)/carrier free & custom formulation / quantity
规格: | 产品价格: | ¥请询价 | |
---|---|---|---|
规格: | 100 ul (10 western blots) | 产品价格: | ¥请询价 |
规格: | carrier free & custom formulation / quantity | 产品价格: | ¥请询价 |
pathway more info application references datasheet PDF MSDS PDF protocols
Applications Key: W=Western Blotting
Reactivity Key: H=Human
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.
Applications | Reactivity | Sensitivity | MW (kDa) | Source |
---|---|---|---|---|
W | H | Transfected Only | 290 | Rabbit |
Protocols |
|
---|---|
Specificity / Sensitivity | The LRRK2 Antibody is recommended for transfected total LRRK2 only. The LRRK2 antibody detects a background band in extracts of wild-type and LRRK2 knock-out mouse brain at ~290kD. |
Source / Purification | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide surrounding Gly2090 of human LRRK2. Antibodies are purified by protein A and peptide affinity chromatography. |
Background | Parkinson’s disease (PD), the second most common neurodegenerative disease after Alzheimer’s, is a progressive movement disorder characterized by rigidity, tremors, and postural instability. The pathological hallmark of PD is progressive loss of dopaminergic neurons in the substantia nigra of the ventral midbrain and the presence of intracellular Lewy bodies (protein aggregates of α-synuclein, ubiquitin, and other components) in surviving neurons of the brain stem (1). Various genes and loci (α-synuclein/PARK1 and 4, parkin/PARK2, UCH-L1/PARK5, PINK1/PARK6, DJ-1/PARK7, LRRK2/PARK8, synphilin-1, and NR4A2) are genetically linked to PD (2).Leucine-rich repeat kinase 2 (LRRK2) contains amino-terminal leucine-rich repeats (LRR), a Ras-like small GTP binding protein-like (ROC) domain, an MLK protein kinase domain, and a carboxy-terminal WD40 repeat domain. At least 20 LRRK2 mutations have been linked to PD-the G2019S mutation being the most prevalent (3). The G2019S mutation causes increased LRRK2 kinase activity, which induces a progressive reduction in neurite length, leading to progressive neurite loss and decreased neuronal survival (4). The MLK inhibitor CEP-1347 is being tested in PD clinical trials, indicating the potential value of LRRK2 as a therapeutic target for treatment of PD (5). |
Application References | Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know! |
Companion Products |
For Research Use Only. Not For Use In Diagnostic Procedures. |
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。